阿根廷婴儿治疗前HIV耐药与亚型:暴露与未暴露于抗逆转录病毒药物者的比较
该研究对2007–2014年出生的115名HIV-1感染婴儿在启动一线ART前进行基因型检测,评估治疗前耐药(PDR)和亚型。总体PDR为30%,未暴露婴儿中 transmitted drug resistance 为32%;暴露婴儿出现多类耐药,并确认一例三重耐药病毒垂直传播。BF重组型占74%。
要点
- 未暴露婴儿PDR达32%,提示耐药传播水平高。
- 暴露婴儿出现多类耐药,NNRTI高水平耐药比例>50%。
- BF重组型为优势亚型,占74%。
核心结论
- 阿根廷HIV-1感染婴儿的PDR水平居报道最高之列,可能危及终身抑制性ART和当前PMTCT方案疗效。
研究设计与样本
- 对115名2007–2014年出生、中位年龄2.3月的HIV-1感染婴儿,在启动一线ART前行HIV-1基因型检测以筛查耐药突变,并用系统发育和重组分析鉴定亚型。
主要发现
- 115名婴儿中34名检出耐药突变,任何ARV的PDR为30%,PI为3.5%,NRTI为12%,NNRTI为22%。
- 22名(19.1%)未暴露于ARV,其传播性耐药为32%(PI 5%、NRTI 9%、NNRTI 18%)。
- 93名暴露婴儿中,28名(24.3%)接受短程齐多夫定单药预防,25名(21.7%)接受基于奈韦拉平的预防,12名(10.4%)接受围产期婴儿齐多夫定预防+母亲含NNRTI联合ART,28名(24.3%)接受围产期婴儿齐多夫定预防+母亲含PI联合ART。
- 暴露婴儿显示多类ARV耐药,并确认一例三重耐药病毒垂直传播。
- 在至少一个耐药突变的婴儿中,无论ARV暴露情况,耐药模式预测NNRTI高水平耐药的比例相似且>50%。
关键数值与推荐
- 总体PDR:任何ARV 30%(34/115),PI 3.5%,NRTI 12%,NNRTI 22%。
- 未暴露婴儿传播性耐药:32%(PI 5%、NRTI 9%、NNRTI 18%)。
- 亚型分布:BF重组74%,B亚型20%,C亚型3%,新型AG和AB重组3%。
临床怎么用
- 对HIV感染婴儿启动ART前应重视基线耐药检测,尤其NNRTI耐药预测比例高。
- 暴露婴儿可能出现多类耐药,需考虑含PI或整合酶抑制剂的方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the prevalence and patterns of pre-treatment HIV drug resistance (PDR) and HIV-1 subtype in infants from Argentina with exposure to different antiretroviral drugs (ARVs) for the prevention of mother-to-child transmission (PMTCT). PATIENTS AND METHODS: HIV-1 genotyping was performed in 115 infants (median age = 2.3 months) born between 2007 and 2014 to screen for drug resistance mutations (DRMs) before starting first-line ART. HIV-1 subtype was characterized by phylogenetic and recombination analysis. RESULTS: Overall, DRMs were found in 34 of 115 infants (PDR level 30% to any ARV, 3.5% to PIs, 12% to NRTIs and 22% to NNRTIs). Of the 115 infants, 22 (19.1%) were ARV-unexposed. Another 93 were ARV-exposed: 28 (24.3%) to short-course zidovudine monotherapy ARV prophylaxis; 25 (21.7%) to nevirapine-based ARV prophylaxis; 12 (10.4%) to perinatal infant zidovudine prophylaxis + maternal combination ART with NNRTIs; and 28 (24.3%) to perinatal infant zidovudine prophylaxis+maternal combination ART with PIs. Transmitted drug resistance among ARV-unexposed infants was 32% (5% to PIs, 9% to NRTIs and 18% to NNRTIs). ART-exposed infants showed multi-class ARV resistance. Importantly, vertical transmission of a triple-class-resistant virus was confirmed in one case. Patterns of DRMs predicted high-level resistance to NNRTIs in a similar and high proportion (>50%) of infants with at least one DRM independently of ARV exposure. BF recombinants were found in 74%, subtype B in 20%, subtype C in 3% and novel AG and AB recombinants in 3%. CONCLUSIONS: PDR in HIV-1-infected children from Argentina is among the highest reported, jeopardizing successful lifelong suppressive ART as well as the efficacy of current PMTCT regimens.
引用
- Aulicino PC, Zapiola I, Kademian S, et al. Pre-treatment drug resistance and HIV-1 subtypes in infants from Argentina with and without exposure to antiretroviral drugs for prevention of mother-to-child transmission. J Antimicrob Chemother. 2019. PMID: 30517632. doi:10.1093/jac/dky486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。